© 2025 by Trienix Pharma. Powered and secured by Wix
Our science
Our lead programs are based on synthetic analogs of Protectin DX (PDX), a specialized pro-resolving mediator (SPM) derived from DHA, with potent anti-inflammatory and pro-resolving properties. Recent discoveries have identified GPR37, a G protein-coupled receptor expressed in immune cells, as a key target mediating the effects of PDX. By engaging GPR37, our compounds trigger cellular pathways that promote resolution of inflammation, limiting tissue damage, and chronic diseases.
Mechanism of action
The action of our synthetic PDX analogs are mediated by GPR37-mediated mechanisms, leading to disease-modifying therapies for metabolic conditions (e.g., T2D, MASLD), post-operative and neuropathic pain, and inflammation associated infectious diseases. Through structure-guided drug design and translational pharmacology, we are building a pipeline of novel, safe, and effective therapeutics that go beyond symptom control to truly change disease trajectories.
GPR37
Key articles
